The firm is the first and only U.S. affiliate dedicated to the biotech investment of Mirae Asset, a prominent global financial group overseeing nearly $600bn AUM across a diversified platform, who has ...

On Second Thought Wednesday's headline on Ignites (a paywalled trade-industry site, no link) read, "Target-Date Funds Can't Beat 60/40 Funds: Study." I assumed the study compared the total returns of ...

There’s an ongoing shift in the dynamic between institutional investors and their managers today. Asset owners are enjoying increasing access to progressively more powerful analytical technology, ...

Clinical trial tech company Science 37 announced Thursday it has acquired a life science platform from Vault Health, which offers COVID-19 testing and health-screening services for employers. Science ...

A new data science team will be established at JP Morgan Asset Management, led by the firm’s Asia Pacific head of equity trading who expands his role as head of data science. The head of equity ...

On Apr 7, we issued an updated research report on Ventas, Inc. VTR. The company’s capital allocation to office segment assets, including life science, medical office buildings (MOBs) and research & ...

This popular investment strategy balances returns with risk by dividing a portfolio among various types of investments. The most popular asset classes are equities, fixed-income and cash equivalents.

Next Science Ltd ( ($AU:NXS) ) has shared an announcement. Next Science Limited has applied to be voluntarily removed from the ASX official list ...

Our Weekly View is typically a timely look at recent market-moving news, what RiverFront thinks about it, and how it may or may not affect our portfolio positioning. Today is a bit different. We are ...